English Release 23-July 2014
- Prime Minister's Office
- PM releases Biography of Sardar Vallabhbhai Patel in Braille
- PM offers floral tributes to Bal Gangadhar Tilak
- Department of Space
- GSLV Project
- SAARC Satellite
- Pricing of Satellite Transponders
- Min for Develop. of North-East Region
- Funds for North Eastern Council
- NGO Funding in North East
- Priority Sectors in North East
- Min of Commerce & Industry
- Trade Agreement with Malaysia
- Trade from Nathu La Border in Sikkim
- Trade with Neighbouring Countries
- Unctad Report on FDI
- Roadmap to Boost Investment Between Japan and India
- FDI in Railways
- Promotion of Services Sector Exports
- Financial Assistance to Madhya Pradesh for New Industrial Development Hubs
- Strengthening of Indian Patent Office
- Evaluation of Impact of FTAS
Agreement Signed with China for Setting up Chinese Industrial Parks
- Trade Relations with Pakistan
- Min of Culture
- Ticket Counters at National Monuments
- Nomination for World Heritage Site Status
- Heritage Site Abha-Neri in Bandikui, Rajasthan
- Min of Labour & Employment
- Housing Facilities for Tea Garden Labourers
- Liberalisation of Labour Laws
- Review of the Works of DGMS
- Checking Discrimination of Workers in Incorporated Unorganised Enterprises
- Criteria of Employees for Coming Under Purview of EPFO
- Rehabilitation of Freed Child Labourers
- Min of Micro,Small & Medium Enterprises
- National Awards to Entrepreneurs
- Funds for EDP
- Revival of Small and Medium Enterprises
- SFURTI Scheme
- Min of Mines
- Land Allotted to Private Parties for Mining
- Revision of Royalty on Minerals
- Functioning Mines in the Country
- Mining Activities Prohibited by Apex Court
Justice Shah Commission Report on Illegal Mining
- Mineral Production during May 2014
- Min of Overseas Indian Affairs
- Recruitment Agencies
- Overseas Indian Centres
- Illegal Migration
- Min of Petroleum & Natural Gas
- Global crude oil price of Indian Basket increased to US$ 105.99. per bbl on 22.07.2014
- Min of Steel
- Modernisation and Expansion of SAIL
- Gap between Production and Demand of Iron Ore in the Country
- Iron Ore Mining Area Allotted to VISP/SAIL
- Min of Urban Development
- Government working on the concept and contours of ‘Smart Cities’ Scheme, says Shri M.Venkaiah Naidu
- Min of Women and Child Development
- 400 districts already covered by the Strengthened & Resurrected ICDS Scheme
- Shelter based schemes for women may be brought under a comprehensive Umbrella Scheme
- Min of Youth Affairs & Sports
- Issue of Indian Players Wearing Turban
Ministry of Health and Family Welfare11-March, 2011 15:34 IST
|The Central Government has prohibited six drugs on the recommendations of the Expert Committee constituted by DTAB in view of the safety issues involved in the use of these drugs by a Gazette Notification dated 10.02.2011 with immediate effect. The names of these drugs along with the brief reasons for their ban are furnished below:|
1. Nimesulide formulations in children below 12 years of age - Nimesulide containing products are not permitted in many countries in children under 12 years of age. The drug has been considered to be hepatotoxic and children are considered more susceptible to hepatotoxicity.
2. Cisapride and its formulations for human use - Use of this drug is reported to be associated with increased risk of serious cardiac arrhythmia.
3. Phenylpropanolamine and its formulations for human use - Use of this drug is associated with risk of hypertensive episodes like cardiac congestive failures and hemorrhagic strokes.
4. Human Placental Extract and its formulations for human use - There is no clear evidence of efficacy of this drug in most of the conditions and there are safety concerns like transmission of blood borne infections, immunoreactions and unwanted exposure to hormones associated with its use.
5. Sibutramine and its formulations for human use - Use of this drug is associated with increased risk of cardiovascular events such as heart attack and stroke.
6. R-Sibutramine and its formulations for human use - Use of this drug is associated with increased risk of cardiovascular events such as heart attack and stroke.
Apart from the aforementioned six drugs banned recently, the following drugs have been banned during the last three years:
1. Rosiglitazone, on 12th November, 2010 - Use of this drug is associated with increased risk of cardiovascular events such as congestive heart failure and myocardial infarction.
2. Rimonabant, on 11th December, 2009 - Use of this drug is associated with increased risk of psychiatric side effects.
3. Diclofenac and its formulations for animal use, on 4th July, 2008 - Extensive use of this drug in animals was leading to harmful effects on vultures. The vulture population was depleting as it was observed that vultures fed on carcass of animals treated with diclofenac were dying.
The decision to ban or withdraw a drug by the regulatory authorities is normally based on the risk assessment process, which is influenced by a number of factors such as disease pattern in a country, indications and dosages of the drug permitted, varying reactions of certain ethnic groups in a given population, availability of safer substitutes and overall safety profile of the drug. These conditions are different for different countries. It is for this reason that a drug banned / restricted in one country may continue to be marketed in other countries. There is a well laid out mechanism in India to review the status of the drug formulations as and when any serious adverse event is reported in the International journals, WHO Newsletters or when a drug formulation is reported to have been banned / withdrawn in some countries. The use of the drug, so reported, is assessed in consultation with the expert committees set up for the purpose, based on available technical information, benefit-risk ratio, local needs and availability of safer alternatives etc. The Central Government prohibit manufacture and sale of drugs in the country under Section 26A of the Drugs and Cosmetics Act, 1940.
This information was given by Minister of Health & Family Welfare Sh. Ghulam Nabi Azad in reply to a question in the Lok Sabha today.
(Release ID :70841)